PBC
MCID: PRM006
MIFTS: 62

Primary Biliary Cirrhosis (PBC)

Categories: Gastrointestinal diseases, Genetic diseases, Immune diseases, Liver diseases, Rare diseases

Aliases & Classifications for Primary Biliary Cirrhosis

MalaCards integrated aliases for Primary Biliary Cirrhosis:

Name: Primary Biliary Cirrhosis 12 74 52 58 36 15 37 17 71 32
Primary Biliary Cholangitis 52 58
Biliary Liver Cirrhosis 12 17
Pbc 52 58
Chronic Nonsuppurative Destructive Cholangitis 12
Familial Primary Biliary Cirrhosis 52
Biliary Cirrhosis Primary 54
Liver Cirrhosis, Biliary 43
Cholestatic Cirrhosis 12
Biliary Cirrhosis 71
Hanot Syndrome 58

Characteristics:

Orphanet epidemiological data:

58
primary biliary cholangitis
Prevalence: 1-9/100000 (Europe),1-5/10000 (Worldwide),1-9/100000 (Worldwide),1-5/10000 (Europe),1-5/10000 (Spain),1-9/100000 (Iceland),1-5/10000 (Iceland),1-9/100000 (Netherlands),1-5/10000 (Netherlands),1-9/100000 (Denmark),1-5/10000 (Denmark),1-9/100000 (Finland),1-5/10000 (Finland),1-5/10000 (United Kingdom),1-9/100000 (United States),1-5/10000 (United States),1-9/100000 (Canada),1-5/10000 (Canada),1-9/100000 (Australia),1-9/100000 (Israel),1-9/100000 (China),1-9/100000 (Brunei Darussalam),1-5/10000 (Greece),1-9/100000 (Greece),1-9/100000 (United Kingdom); Age of onset: Adolescent,Adult,Elderly;

Classifications:

Orphanet: 58  
Rare hepatic diseases


Summaries for Primary Biliary Cirrhosis

NIH Rare Diseases : 52 Primary biliary cholangitis (PBC) is a chronic, progressive liver disease in which the bile ducts become inflamed and damaged. This leads to the buildup of bile and causes liver problems such as scarring, cirrhosis (scarring and poor liver function), and eventual liver failure . PBC is more common in women. Many people do not have symptoms when they are first diagnosed and may not develop symptoms for several years. Early symptoms may include fatigue (the most common symptom), itchy skin (pruritus ), and abdominal pain. As the disease progresses, people with PBC may develop weakness, nausea, diarrhea, swelling in the legs and feet (edema), bone and joint pain, jaundice , dark urine, and xanthomas . The symptoms of PBC can significantly impair quality of life. The diagnosis of PBC may involve blood tests, imaging studies (such as X-ray or ultrasound ), and sometimes, a liver biopsy . Blood tests may include tests for anti-mitochondrial antibodies (which may confirm the diagnosis), liver function tests , and cholesterol tests . Abnormal blood test results commonly lead to the diagnosis in people with PBC who do not have symptoms. PBC is considered an autoimmune disease in which the immune system malfunctions and mistakenly attacks a person's healthy bile duct cells , causing the inflammation and damage. It is thought to be caused by a combination of genetic susceptibility and environmental triggers (multifactorial inheritance ). The first treatment recommended for people with PBC is ursodiol , also called ursodeoxycholic acid (UDCA), which has been shown to slow disease progression and reduce the need for a liver transplant. Obeticholic acid (OCA) is available as a second-line treatment either in combination with UDCA (in those with an inadequate response to UDCA), or by itself (in those who are not able to tolerate UDCA). The symptoms of PBC typically do not improve with UDCA or OCA, so individual symptoms are treated separately. A liver transplant may be needed when PBC leads to liver failure. The rate of progression varies greatly among people with PBC, and the disease may progress over many decades before resulting in end-stage liver disease and its complications.

MalaCards based summary : Primary Biliary Cirrhosis, also known as primary biliary cholangitis, is related to connective tissue disease and non-alcoholic fatty liver disease. An important gene associated with Primary Biliary Cirrhosis is DLAT (Dihydrolipoamide S-Acetyltransferase), and among its related pathways/superpathways are MicroRNAs in cancer and Parkinsons Disease Pathway. The drugs Abatacept and Sorafenib have been mentioned in the context of this disorder. Affiliated tissues include Umbilical Cord, liver and t cells, and related phenotypes are cirrhosis and biliary cirrhosis

Disease Ontology : 12 A liver cirrhosis characterized by chronic and slow progressive destruction of intrahepatic bile ducts.

KEGG : 36 Primary biliary cirrhosis (PBC) is a chronic, progressive cholestatic liver disease characterised by destruction of small intrahepatic bile ducts, eventually leading to fibrosis and potential cirrhosis. Patients are usually middle-aged women and presents in the fifth or sixth decade of life. The most common symptoms are pruritus. It is not clear what causes PBC. It may be relate to problems in the autoimmune mechanism. The increased risk of genetic predisposition and environmental factors (infectious or toxic agents) trigger the disease. Ursodeoxycholic acid is currently the only medicine approved for the treatment of the disease.

Wikipedia : 74 Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune... more...

Related Diseases for Primary Biliary Cirrhosis

Diseases in the Primary Biliary Cirrhosis family:

Biliary Cirrhosis, Primary, 1 Biliary Cirrhosis, Primary, 2
Biliary Cirrhosis, Primary, 3 Biliary Cirrhosis, Primary, 4
Biliary Cirrhosis, Primary, 5

Diseases related to Primary Biliary Cirrhosis via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 640, show less)
# Related Disease Score Top Affiliating Genes
1 connective tissue disease 30.8 MIR223 MIR17 MIR150 MIR122
2 non-alcoholic fatty liver disease 30.4 MIR451A MIR30D MIR17 MIR122
3 arteries, anomalies of 30.2 MIR296 MIR223 MIR17 MIR150 MIR122
4 systemic lupus erythematosus 30.1 MIR346 MIR324 MIR30D MIR296 MIR223 MIR197
5 glioma susceptibility 1 29.9 MIR451A MIR326 MIR296 MIR197
6 intestinal disease 29.9 MIRLET7B MIR324 MIR20A MIR17 MIR150
7 muscular dystrophy, duchenne type 29.8 MIR361 MIR30D MIR299 MIR197 ENSG00000266919
8 psoriasis 29.7 MIR326 MIR20A MIR197 MIR17 MIR133B MIR122
9 gastrointestinal system disease 29.5 MIRLET7B MIR324 MIR223 MIR20A MIR17 MIR150
10 reynolds syndrome 12.7
11 biliary cirrhosis, primary, 1 12.2
12 biliary cirrhosis, primary, 4 11.8
13 biliary cirrhosis, primary, 5 11.8
14 biliary cirrhosis, primary, 2 11.8
15 biliary cirrhosis, primary, 3 11.8
16 liver cirrhosis 11.7
17 primary biliary cholangitis/primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome 11.3
18 cholangitis 11.2
19 autoimmune disease 11.1
20 liver disease 11.1
21 cholestasis 11.1
22 autoimmune hepatitis 11.1
23 sclerosing cholangitis 11.0
24 cholangitis, primary sclerosing 11.0
25 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.9
26 varicose veins 10.9
27 portal hypertension 10.9
28 systemic scleroderma 10.8
29 viral hepatitis 10.8
30 scleroderma, familial progressive 10.8
31 esophageal varix 10.7
32 raynaud phenomenon 10.7
33 osteoporosis 10.7
34 thyroiditis 10.7
35 sjogren syndrome 10.7
36 crest syndrome 10.7
37 sarcoidosis 1 10.7
38 bone disease 10.7
39 hepatocellular carcinoma 10.7
40 bone mineral density quantitative trait locus 8 10.7
41 bone mineral density quantitative trait locus 15 10.7
42 polymyositis 10.6
43 hypercholesterolemia, familial, 1 10.6
44 osteomalacia 10.6
45 hepatitis 10.6
46 deficiency anemia 10.5
47 hemolytic anemia 10.5
48 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.5
49 graft-versus-host disease 10.5
50 telangiectasis 10.5
51 renal tubular acidosis 10.5
52 splenomegaly 10.5
53 glomerulonephritis 10.5
54 purpura 10.5
55 celiac disease 1 10.5
56 acute cystitis 10.5
57 hepatitis c 10.5
58 rheumatoid arthritis 10.5
59 anemia, autoimmune hemolytic 10.5
60 ulcerative colitis 10.5
61 lupus erythematosus 10.5
62 hashimoto thyroiditis 10.5
63 calcinosis 10.5
64 hepatic encephalopathy 10.5
65 hypothyroidism 10.5
66 vasculitis 10.5
67 neuropathy 10.5
68 lichen planus 10.5
69 autonomic dysfunction 10.5
70 rickets 10.5
71 hepatic coma 10.5
72 47,xyy 10.5
73 membranous nephropathy 10.4
74 colitis 10.4
75 keratoconjunctivitis sicca 10.4
76 thrombocytopenia 10.4
77 bilirubin metabolic disorder 10.4
78 lung disease 10.4
79 fatty liver disease 10.4
80 hypereosinophilic syndrome 10.4
81 fibrosis of extraocular muscles, congenital, 1 10.4
82 hepatitis c virus 10.4
83 interstitial lung disease 10.4
84 arthritis 10.4
85 cytokine deficiency 10.4
86 vitiligo-associated multiple autoimmune disease susceptibility 6 10.4
87 vitiligo-associated multiple autoimmune disease susceptibility 1 10.4
88 pulmonary hypertension 10.4
89 bone resorption disease 10.4
90 hepatitis a 10.4
91 gastritis 10.4
92 keratoconjunctivitis 10.4
93 nodular regenerative hyperplasia 10.4
94 encephalopathy 10.4
95 pernicious anemia 10.4
96 cholangiocarcinoma 10.4
97 exanthem 10.4
98 obstructive jaundice 10.4
99 bacteriuria 10.4
100 intrahepatic cholangiocarcinoma 10.4
101 chronic graft versus host disease 10.4
102 temporal arteritis 10.4
103 myasthenia gravis 10.4
104 myeloma, multiple 10.4
105 lymphoma 10.4
106 non-alcoholic steatohepatitis 10.4
107 antiphospholipid syndrome 10.4
108 lipid metabolism disorder 10.4
109 crohn's disease 10.4
110 bile duct disease 10.4 MIR324 MIR17 MIR150 DLAT
111 biliary tract disease 10.3 MIR324 MIR17 MIR150 DLAT
112 aortic disease 10.3 MIR17 MIR150 MIR122
113 aortic valve disease 2 10.3 MIR223 MIR17 MIR150
114 inflammatory bowel disease 10.3
115 cholelithiasis 10.3
116 graves' disease 10.3
117 extrahepatic cholestasis 10.3
118 alcoholic liver cirrhosis 10.3
119 chronic cholangitis 10.3
120 autoimmune hepatitis type 1 10.3
121 pleural disease 10.3 MIRLET7B MIR223 MIR17
122 myositis 10.3
123 thrombocytopenic purpura, autoimmune 10.3
124 proteasome-associated autoinflammatory syndrome 1 10.3
125 gallbladder disease 1 10.3
126 chlamydia 10.3
127 hepatitis b 10.3
128 arthropathy 10.3
129 myopathy 10.3
130 pancreatitis 10.3
131 collagen disease 10.3
132 miyoshi muscular dystrophy 1 10.3 MIR299 MIR223
133 bile duct adenocarcinoma 10.3 MIR324 MIR17 MIR150
134 chlamydia pneumonia 10.3
135 sialadenitis 10.3
136 diarrhea 10.3
137 mixed connective tissue disease 10.3
138 pulmonary fibrosis 10.3
139 localized scleroderma 10.3
140 bullous pemphigoid 10.3
141 amyloidosis 10.3
142 distal renal tubular acidosis 10.3
143 mycobacterium gordonae 10.3
144 cryptogenic cirrhosis 10.3
145 acute liver failure 10.3
146 connective tissue cancer 10.2 MIR223 MIR197 MIR17 MIR150
147 atherosclerosis susceptibility 10.2
148 hypercarotenemia and vitamin a deficiency, autosomal dominant 10.2
149 multiple sclerosis 10.2
150 lichen sclerosus et atrophicus 10.2
151 helicobacter pylori infection 10.2
152 xanthomatosis 10.2
153 fanconi renotubular syndrome 2 10.2
154 dermatomyositis 10.2
155 fanconi syndrome 10.2
156 keratomalacia 10.2
157 hyperparathyroidism 10.2
158 pericarditis 10.2
159 sensory peripheral neuropathy 10.2
160 dermatitis 10.2
161 bronchiolitis 10.2
162 turner syndrome 10.2
163 b-cell lymphoma 10.2
164 hyperthyroidism 10.2
165 peritonitis 10.2
166 48,xyyy 10.2
167 microscopic polyangiitis 10.2
168 retroperitoneal fibrosis 10.2
169 oral cavity cancer 10.2 MIRLET7B MIR17 MIR150
170 rectum cancer 10.2 MIRLET7B MIR20A MIR17 MIR150
171 retinal cancer 10.2 MIRLET7B MIR361 MIR17
172 spinal disease 10.2 MIR223 MIR17 MIR150
173 infratentorial cancer 10.2 MIR324 MIR20A MIR17
174 glucose metabolism disease 10.2 MIR223 MIR20A MIR17 MIR150
175 overnutrition 10.2 MIR223 MIR17 MIR122
176 ocular cancer 10.2 MIRLET7B MIR361 MIR17
177 pituitary adenoma 10.2 MIR223 MIR212 MIR197
178 pulmonary hypertension, primary, 1 10.2
179 australia antigen 10.2
180 huntington disease-like 3 10.2
181 huntington disease-like 2 10.2
182 autoimmune pancreatitis 10.2
183 respiratory failure 10.2
184 tetanus 10.2
185 pyelonephritis 10.2
186 chondrocalcinosis 10.2
187 uveitis 10.2
188 polyneuropathy 10.2
189 enthesopathy 10.2
190 granulomatous hepatitis 10.2
191 gastric antral vascular ectasia 10.2
192 bronchiolitis obliterans 10.2
193 myelitis 10.2
194 skin disease 10.2
195 syphilis 10.2
196 peripheral nervous system disease 10.2
197 granulocytopenia 10.2
198 transverse myelitis 10.2
199 dysphagia 10.2
200 nemaline myopathy 10.2 MIR361 MIR299 MIR223 ENSG00000266919
201 kidney cancer 10.2 MIR20A MIR17 MIR150 MIR122
202 nasopharyngeal disease 10.2 MIR324 MIR296 MIR17
203 esophageal disease 10.2 MIR361 MIR223 MIR17
204 autonomic nervous system neoplasm 10.2 MIR324 MIR20A MIR17
205 laryngeal disease 10.2 MIRLET7B MIR296 MIR20A MIR17
206 pharynx cancer 10.2 MIR324 MIR296 MIR17
207 peripheral nervous system neoplasm 10.2 MIR324 MIR20A MIR17
208 pancreas disease 10.2 MIRLET7B MIR324 MIR17 MIR150
209 urinary system disease 10.2 MIR324 MIR223 MIR17 MIR150
210 glioma 10.1 MIR328 MIR296 MIR20A MIR17
211 endocrine system disease 10.1 MIRLET7B MIR324 MIR17 MIR150
212 immune system disease 10.1 MIR223 MIR20A MIR17 MIR150 MIR122
213 central nervous system cancer 10.1 MIR324 MIR296 MIR17 MIR150
214 colonic disease 10.1 MIR324 MIR20A MIR17 MIR150
215 cholestasis, progressive familial intrahepatic, 1 10.1
216 cardiac conduction defect 10.1
217 lymphoma, mucosa-associated lymphoid type 10.1
218 alkaline phosphatase, plasma level of, quantitative trait locus 1 10.1
219 fibrosclerosis, multifocal 10.1
220 hemochromatosis, type 1 10.1
221 myelofibrosis 10.1
222 taqi polymorphism 10.1
223 yemenite deaf-blind hypopigmentation syndrome 10.1
224 immunoglobulin alpha deficiency 10.1
225 igg4-related disease 10.1
226 interstitial nephritis 10.1
227 vitamin k deficiency bleeding 10.1
228 arteriovenous malformation 10.1
229 portal vein thrombosis 10.1
230 allergic hypersensitivity disease 10.1
231 pancytopenia 10.1
232 biliary atresia 10.1
233 suppurative cholangitis 10.1
234 alcohol use disorder 10.1
235 limited scleroderma 10.1
236 vascular disease 10.1
237 macrocytic anemia 10.1
238 hepatitis e 10.1
239 pneumonia 10.1
240 myocarditis 10.1
241 night blindness 10.1
242 chronic fatigue syndrome 10.1
243 measles 10.1
244 atrophic gastritis 10.1
245 evans' syndrome 10.1
246 hepatopulmonary syndrome 10.1
247 hypoglycemia 10.1
248 atp8b1 deficiency 10.1
249 banti's syndrome 10.1
250 cytomegalovirus infection 10.1
251 tremor 10.1
252 autoimmune hepatitis type 2 10.1
253 pik3ca-related overgrowth syndrome 10.1
254 leiomyoma, uterine 10.1 MIR451A MIR212 MIR197 MIR150
255 acquired metabolic disease 10.1 MIRLET7B MIR223 MIR20A MIR17 MIR150
256 upper respiratory tract disease 10.1 MIR324 MIR296 MIR20A MIR17
257 cystic fibrosis 10.1
258 atrial standstill 1 10.0
259 dowling-degos disease 1 10.0
260 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
261 ocular motor apraxia 10.0
262 insulin-like growth factor i 10.0
263 dermatitis herpetiformis, familial 10.0
264 body mass index quantitative trait locus 1 10.0
265 alpha-1-antitrypsin deficiency 10.0
266 glucocorticoid resistance, generalized 10.0
267 hydrops, lactic acidosis, and sideroblastic anemia 10.0
268 hyperlipoproteinemia, type iii 10.0
269 lipoprotein quantitative trait locus 10.0
270 autoimmune gastritis 10.0
271 primary cutaneous amyloidosis 10.0
272 metabolic acidosis 10.0
273 intrahepatic cholestasis of pregnancy 10.0
274 xerophthalmia 10.0
275 gastric ulcer 10.0
276 cholecystolithiasis 10.0
277 hemopericardium 10.0
278 autonomic neuropathy 10.0
279 pericardial effusion 10.0
280 hepatorenal syndrome 10.0
281 plica syndrome 10.0
282 neutropenia 10.0
283 alcoholic hepatitis 10.0
284 leukemia 10.0
285 secondary hyperparathyroidism 10.0
286 hereditary hemorrhagic telangiectasia 10.0
287 hereditary spherocytosis 10.0
288 crescentic glomerulonephritis 10.0
289 gout 10.0
290 skin sarcoidosis 10.0
291 gonadal dysgenesis 10.0
292 duodenal ulcer 10.0
293 dental caries 10.0
294 relapsing-remitting multiple sclerosis 10.0
295 thrombophilia 10.0
296 splenic infarction 10.0
297 synovitis 10.0
298 cryoglobulinemia 10.0
299 adenocarcinoma 10.0
300 histiocytosis 10.0
301 plague 10.0
302 pyoderma 10.0
303 somatostatinoma 10.0
304 rapidly progressive glomerulonephritis 10.0
305 kidney disease 10.0
306 bronchitis 10.0
307 severe combined immunodeficiency 10.0
308 fibromyalgia 10.0
309 hypersplenism 10.0
310 adenoma 10.0
311 active peptic ulcer disease 10.0
312 peptic ulcer disease 10.0
313 chronic kidney disease 10.0
314 dermatitis herpetiformis 10.0
315 herpes zoster 10.0
316 pyoderma gangrenosum 10.0
317 meningitis 10.0
318 encephalitis 10.0
319 noma 10.0
320 polyarteritis nodosa 10.0
321 muscular dystrophy 10.0
322 haemophilus influenzae 10.0
323 hemangioendothelioma 10.0
324 oral lichen planus 10.0
325 undifferentiated connective tissue disease 10.0
326 epithelioid hemangioendothelioma 10.0
327 avascular necrosis 10.0
328 igg4-related sclerosing cholangitis 10.0
329 argyria 10.0
330 overgrowth syndrome 10.0
331 undetermined colitis 10.0
332 cervix disease 10.0 MIR361 MIR212 MIR17
333 ovarian cancer 9.9
334 trigeminal neuralgia 9.9
335 leukemia, acute lymphoblastic 3 9.9
336 helix syndrome 9.9
337 muscular atrophy 9.9
338 paresthesia 9.9
339 breast cancer 9.9
340 colorectal cancer 9.9
341 alagille syndrome 1 9.9
342 major depressive disorder 9.9
343 multinodular goiter 9.9
344 pica disease 9.9
345 acute cholangitis 9.9
346 hyperuricemia 9.9
347 nonspecific interstitial pneumonia 9.9
348 ischemia 9.9
349 diabetes mellitus 9.9
350 light chain deposition disease 9.9
351 cerebral hypoxia 9.9
352 chronic pain 9.9
353 hypoxia 9.9
354 rapidly involuting congenital hemangioma 9.9
355 thyroid carcinoma 9.9
356 squamous cell carcinoma, head and neck 9.9 MIR324 MIR299 MIR197 MIR17 MIR150 MIR122
357 glucocorticoid-induced osteoporosis 9.9
358 exocrine pancreatic insufficiency 9.9
359 klatskin's tumor 9.9
360 cerebral aneurysms 9.9
361 central nervous system disease 9.9 MIRLET7B MIR324 MIR223 MIR212 MIR17 MIR150
362 familial intrahepatic cholestasis 9.9
363 acanthosis nigricans 9.9
364 pfeiffer syndrome 9.9
365 amyotrophic lateral sclerosis 1 9.9
366 spondyloarthropathy 1 9.9
367 bladder cancer 9.9
368 cardiac arrhythmia 9.9
369 immunoglobulin a deficiency 1 9.9
370 hyperalphalipoproteinemia 1 9.9
371 ige responsiveness, atopic 9.9
372 ocular cicatricial pemphigoid 9.9
373 raynaud disease 9.9
374 renal tubular acidosis, proximal 9.9
375 schistosoma mansoni infection, susceptibility/ 9.9
376 syringomyelia, noncommunicating isolated 9.9
377 triiodothyronine receptor auxiliary protein 9.9
378 diabetes mellitus, type i 9.9
379 eosinophilic fasciitis 9.9
380 factor vii deficiency 9.9
381 hemochromatosis, neonatal 9.9
382 hypervitaminosis a 9.9
383 cholestasis, benign recurrent intrahepatic, 1 9.9
384 lecithin:cholesterol acyltransferase deficiency 9.9
385 leprosy 3 9.9
386 lymphoid interstitial pneumonia 9.9
387 maple syrup urine disease 9.9
388 myxedema 9.9
389 pancreatic cancer 9.9
390 pituitary hormone deficiency, combined, 2 9.9
391 short stature-obesity syndrome 9.9
392 thymoma, familial 9.9
393 graves disease 1 9.9
394 albinism-deafness syndrome 9.9
395 kearns-sayre syndrome 9.9
396 asthma 9.9
397 cd4/cd8 t-cell ratio 9.9
398 diabetes mellitus, insulin-dependent, 12 9.9
399 systemic lupus erythematosus 1 9.9
400 bile duct cysts 9.9
401 dermatitis, atopic 9.9
402 homocysteinemia 9.9
403 reflex sympathetic dystrophy 9.9
404 langerhans cell histiocytosis 9.9
405 bone mineral density quantitative trait locus 3 9.9
406 psoriatic arthritis 9.9
407 endometrial cancer 9.9
408 kala-azar 1 9.9
409 leukemia, chronic myeloid 9.9
410 systemic lupus erythematosus 12 9.9
411 acute promyelocytic leukemia 9.9
412 systemic lupus erythematosus 14 9.9
413 gastric cancer 9.9
414 psoriasis 13 9.9
415 barrett esophagus 9.9
416 carbonic anhydrase va deficiency, hyperammonemia due to 9.9
417 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.9
418 acute diarrhea 9.9
419 cryptogenic organizing pneumonia 9.9
420 hypochromic microcytic anemia 9.9
421 diffuse large b-cell lymphoma 9.9
422 lymphoplasmacytic lymphoma 9.9
423 marginal zone b-cell lymphoma 9.9
424 polycystic liver disease 9.9
425 atrioventricular block 9.9
426 colorectal adenoma 9.9
427 colorectal adenocarcinoma 9.9
428 colon adenoma 9.9
429 gastrointestinal carcinoma 9.9
430 cutaneous t cell lymphoma 9.9
431 crohn's colitis 9.9
432 sclerosteosis 9.9
433 ptosis 9.9
434 gallbladder disease 9.9
435 angular cheilitis 9.9
436 waldenstroem's macroglobulinemia 9.9
437 hepatic veno-occlusive disease 9.9
438 mucositis 9.9
439 nodal marginal zone lymphoma 9.9
440 middle east respiratory syndrome 9.9
441 sitosterolemia 9.9
442 acquired von willebrand syndrome 9.9
443 parotitis 9.9
444 endocarditis 9.9
445 siderosis 9.9
446 bacterial infectious disease 9.9
447 gastric lymphoma 9.9
448 pre-eclampsia 9.9
449 premature menopause 9.9
450 duodenum adenocarcinoma 9.9
451 lipoid nephrosis 9.9
452 brucellosis 9.9
453 q fever 9.9
454 henoch-schoenlein purpura 9.9
455 primary hyperparathyroidism 9.9
456 microcytic anemia 9.9
457 cardiac tamponade 9.9
458 iron deficiency anemia 9.9
459 multicentric reticulohistiocytosis 9.9
460 nephrotic syndrome 9.9
461 hypertrophic cardiomyopathy 9.9
462 cryptococcosis 9.9
463 inflammatory spondylopathy 9.9
464 hemosiderosis 9.9
465 aseptic meningitis 9.9
466 goiter 9.9
467 von willebrand's disease 9.9
468 acute leukemia 9.9
469 guillain-barre syndrome 9.9
470 dilated cardiomyopathy 9.9
471 carotid stenosis 9.9
472 focal segmental glomerulosclerosis 9.9
473 neurosarcoidosis 9.9
474 pulmonary sarcoidosis 9.9
475 eclampsia 9.9
476 opisthorchiasis 9.9
477 schistosomiasis 9.9
478 algoneurodystrophy 9.9
479 autoimmune polyendocrine syndrome 9.9
480 acute poststreptococcal glomerulonephritis 9.9
481 selective igg deficiency disease 9.9
482 ascending cholangitis 9.9
483 prostatitis 9.9
484 nodular nonsuppurative panniculitis 9.9
485 panniculitis 9.9
486 urticaria 9.9
487 fungal infectious disease 9.9
488 diffuse scleroderma 9.9
489 thrombocytopenia due to platelet alloimmunization 9.9
490 mental depression 9.9
491 cheilitis 9.9
492 hypogonadism 9.9
493 cholecystitis 9.9
494 hyperinsulinism 9.9
495 drug-induced hepatitis 9.9
496 hyperostosis 9.9
497 constipation 9.9
498 sweat gland cancer 9.9
499 urogenital tuberculosis 9.9
500 vaginitis 9.9
501 myeloproliferative neoplasm 9.9
502 transient cerebral ischemia 9.9
503 pharyngitis 9.9
504 lateral sclerosis 9.9
505 iron metabolism disease 9.9
506 angiodysplasia 9.9
507 agammaglobulinemia 9.9
508 acute interstitial pneumonia 9.9
509 membranoproliferative glomerulonephritis 9.9
510 pulmonary tuberculosis 9.9
511 periarthritis 9.9
512 gingivitis 9.9
513 papillary adenocarcinoma 9.9
514 gallbladder cancer 9.9
515 proctitis 9.9
516 scleredema adultorum 9.9
517 lipomatosis 9.9
518 syringomyelia 9.9
519 thymoma 9.9
520 palmoplantar keratosis 9.9
521 granulomatous myositis 9.9
522 granuloma annulare 9.9
523 porokeratosis 9.9
524 placental insufficiency 9.9
525 insulinoma 9.9
526 mediastinal lipomatosis 9.9
527 tricuspid valve insufficiency 9.9
528 biliary dyskinesia 9.9
529 secondary syphilis 9.9
530 hyperglycemia 9.9
531 hypertrichosis 9.9
532 burning mouth syndrome 9.9
533 granulomatous dermatitis 9.9
534 pustulosis of palm and sole 9.9
535 hypokalemia 9.9
536 proliferative glomerulonephritis 9.9
537 anti-basement membrane glomerulonephritis 9.9
538 thyroid gland disease 9.9
539 chronic inflammatory demyelinating polyradiculoneuropathy 9.9
540 demyelinating polyneuropathy 9.9
541 sleep disorder 9.9
542 congestive heart failure 9.9
543 lymphopenia 9.9
544 progressive multifocal leukoencephalopathy 9.9
545 spondylitis 9.9
546 mitochondrial myopathy 9.9
547 axonal neuropathy 9.9
548 neuroblastoma 9.9
549 end stage renal disease 9.9
550 influenza 9.9
551 mucormycosis 9.9
552 herpes simplex 9.9
553 chickenpox 9.9
554 myeloid leukemia 9.9
555 rubella 9.9
556 mitochondrial encephalomyopathy 9.9
557 liver lymphoma 9.9
558 leishmaniasis 9.9
559 macroglobulinemia 9.9
560 visceral leishmaniasis 9.9
561 achalasia 9.9
562 pemphigus 9.9
563 orbital disease 9.9
564 viral infectious disease 9.9
565 orbital plasma cell granuloma 9.9
566 iridocyclitis 9.9
567 acute myocardial infarction 9.9
568 pulmonary embolism 9.9
569 fasciitis 9.9
570 stomatitis 9.9
571 pulmonary emphysema 9.9
572 tenosynovitis 9.9
573 toxocariasis 9.9
574 tuberculous peritonitis 9.9
575 alopecia 9.9
576 periostitis 9.9
577 aminoaciduria 9.9
578 anca-associated vasculitis 9.9
579 autoimmune encephalitis 9.9
580 autoimmune myocarditis 9.9
581 chromosomal triplication 9.9
582 cutaneous polyarteritis nodosa 9.9
583 cutaneous sclerosis 9.9
584 fasting hypoglycemia 9.9
585 fibrillary glomerulonephritis 9.9
586 frontal fibrosing alopecia 9.9
587 hansen's disease 9.9
588 homologous wasting disease 9.9
589 hypertrichosis lanuginosa, acquired 9.9
590 immunoglobulin g deficiency 9.9
591 klebsiella infection 9.9
592 limbic encephalitis 9.9
593 lymphocytic hypophysitis 9.9
594 superior limbic keratoconjunctivitis 9.9
595 weber syndrome 9.9
596 depression 9.9
597 back pain 9.9
598 dysautonomia 9.9
599 syncope 9.9
600 posttransplant acute limbic encephalitis 9.9
601 systemic autoimmune disease 9.9
602 acute transverse myelitis 9.9
603 endotheliitis 9.9
604 progressive muscular dystrophy 9.9
605 rare hereditary hemochromatosis 9.9
606 chronic actinic dermatitis 9.9
607 acute generalized exanthematous pustulosis 9.9
608 disorder of copper metabolism 9.9
609 eosinophilic colitis 9.9
610 secondary sclerosing cholangitis 9.9
611 hepatoportal sclerosis 9.9
612 methotrexate toxicity 9.9
613 mixed-type autoimmune hemolytic anemia 9.9
614 discoid lupus erythematosus 9.9
615 pemphigus erythematosus 9.9
616 primary hypophysitis 9.9
617 polyendocrinopathy 9.9
618 eye disease 9.9 MIRLET7B MIR361 MIR223 MIR20A MIR17 MIR122
619 disease of mental health 9.9 MIR223 MIR17 MIR122
620 prostate disease 9.8 MIR361 MIR296 MIR223 MIR20A MIR17 MIR150
621 leukemia, chronic lymphocytic 9.8 MIR30D MIR296 MIR223 MIR20A MIR17 MIR150
622 endocrine gland cancer 9.8 MIRLET7B MIR324 MIR223 MIR20A MIR17 MIR150
623 gastrointestinal system cancer 9.8 MIRLET7B MIR324 MIR223 MIR20A MIR17 MIR150
624 female reproductive system disease 9.7 MIR361 MIR324 MIR30D MIR223 MIR20A MIR17
625 lymphatic system cancer 9.7 MIR361 MIR324 MIR223 MIR20A MIR17 MIR150
626 male reproductive organ cancer 9.7 MIR361 MIR296 MIR223 MIR212 MIR20A MIR17
627 male reproductive system disease 9.7 MIR361 MIR296 MIR223 MIR212 MIR20A MIR17
628 nervous system disease 9.6 MIRLET7B MIR324 MIR223 MIR212 MIR20A MIR17
629 thoracic cancer 9.6 MIRLET7B MIR324 MIR296 MIR223 MIR20A MIR17
630 oral squamous cell carcinoma 9.6 MIRLET7B MIR30D MIR296 MIR223 MIR197 MIR17
631 large intestine cancer 9.6 MIRLET7B MIR361 MIR324 MIR223 MIR20A MIR17
632 medulloblastoma 9.5 MIR326 MIR324 MIR30D MIR20A MIR17
633 lung cancer susceptibility 3 9.5 MIR361 MIR324 MIR30D MIR296 MIR212 MIR17
634 lymphatic system disease 9.5 MIR361 MIR324 MIR296 MIR223 MIR20A MIR17
635 hematologic cancer 9.4 MIRLET7B MIR361 MIR324 MIR296 MIR223 MIR20A
636 reproductive system disease 9.4 MIRLET7B MIR361 MIR324 MIR30D MIR223 MIR20A
637 leukemia, acute myeloid 9.2 MIRLET7B MIR451A MIR328 MIR326 MIR324 MIR30D
638 respiratory system disease 8.9 MIRLET7B MIR361 MIR324 MIR30D MIR296 MIR223
639 respiratory system cancer 8.9 MIRLET7B MIR361 MIR324 MIR30D MIR296 MIR223
640 lung cancer 8.4 MIRLET7B MIR451A MIR361 MIR324 MIR30D MIR296

Comorbidity relations with Primary Biliary Cirrhosis via Phenotypic Disease Network (PDN): (showing 7, show less)


Active Peptic Ulcer Disease Acute Cystitis
Cholangitis Deficiency Anemia
Hepatic Encephalopathy Hypothyroidism
Portal Hypertension

Graphical network of the top 20 diseases related to Primary Biliary Cirrhosis:



Diseases related to Primary Biliary Cirrhosis

Symptoms & Phenotypes for Primary Biliary Cirrhosis

Human phenotypes related to Primary Biliary Cirrhosis:

58 31 (showing 33, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 cirrhosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0001394
2 biliary cirrhosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002613
3 conjugated hyperbilirubinemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002908
4 hyperpigmentation of the skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0000953
5 dermatographic urticaria 58 31 hallmark (90%) Very frequent (99-80%) HP:0011971
6 portal hypertension 58 31 frequent (33%) Frequent (79-30%) HP:0001409
7 pruritus 58 31 frequent (33%) Frequent (79-30%) HP:0000989
8 hepatic fibrosis 58 31 frequent (33%) Frequent (79-30%) HP:0001395
9 jaundice 58 31 frequent (33%) Frequent (79-30%) HP:0000952
10 hepatic failure 58 31 frequent (33%) Frequent (79-30%) HP:0001399
11 abnormality of the thyroid gland 58 31 frequent (33%) Frequent (79-30%) HP:0000820
12 orthostatic hypotension 58 31 frequent (33%) Frequent (79-30%) HP:0001278
13 hepatocellular carcinoma 58 31 frequent (33%) Frequent (79-30%) HP:0001402
14 increased circulating igm level 58 31 frequent (33%) Frequent (79-30%) HP:0003496
15 antinuclear antibody positivity 58 31 frequent (33%) Frequent (79-30%) HP:0003493
16 onychomycosis 58 31 frequent (33%) Frequent (79-30%) HP:0012203
17 elevated alkaline phosphatase 58 31 frequent (33%) Frequent (79-30%) HP:0003155
18 abnormality of the intrahepatic bile duct 58 31 frequent (33%) Frequent (79-30%) HP:0011040
19 abnormal circulating lipid concentration 31 frequent (33%) HP:0003119
20 fatigue 58 31 occasional (7.5%) Occasional (29-5%) HP:0012378
21 ascites 58 31 occasional (7.5%) Occasional (29-5%) HP:0001541
22 hepatitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0012115
23 osteoporosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000939
24 celiac disease 58 31 occasional (7.5%) Occasional (29-5%) HP:0002608
25 hypoalbuminemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003073
26 abdominal distention 58 31 occasional (7.5%) Occasional (29-5%) HP:0003270
27 excessive daytime somnolence 58 31 occasional (7.5%) Occasional (29-5%) HP:0001262
28 increased circulating iga level 58 31 occasional (7.5%) Occasional (29-5%) HP:0003261
29 gastrointestinal inflammation 58 31 very rare (1%) Very rare (<4-1%) HP:0004386
30 sleep disturbance 58 Occasional (29-5%)
31 autoimmunity 58 Frequent (79-30%)
32 abnormality of lipid metabolism 58 Frequent (79-30%)
33 recurrent fungal infections 58 Frequent (79-30%)

Drugs & Therapeutics for Primary Biliary Cirrhosis

Drugs for Primary Biliary Cirrhosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 155, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abatacept Approved Phase 4 332348-12-6 10237
2
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
3
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
4
Mycophenolic acid Approved Phase 4 24280-93-1 446541
5
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
6
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
7
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
8
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
9 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
10
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
11
Cefoperazone Approved, Investigational Phase 4 62893-19-0 44185
12
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 441130 64778
13
Teicoplanin Approved, Investigational Phase 4 61036-62-2
14
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
15
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
16 Protein Kinase Inhibitors Phase 4
17 Anti-Bacterial Agents Phase 4
18 Anti-Infective Agents Phase 4
19 Immunologic Factors Phase 4
20 Dermatologic Agents Phase 4
21 Immunosuppressive Agents Phase 4
22 Antirheumatic Agents Phase 4
23 Antitubercular Agents Phase 4
24 Methylprednisolone Acetate Phase 4
25 Cyclosporins Phase 4
26 Antifungal Agents Phase 4
27 Calcineurin Inhibitors Phase 4
28 Antibiotics, Antitubercular Phase 4
29 Alkylating Agents Phase 4
30 Antiprotozoal Agents Phase 4
31 Antiparasitic Agents Phase 4
32 Sulperazone Phase 4
33
Fenofibrate Approved Phase 3 49562-28-9 3339
34
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
35
Metronidazole Approved Phase 2, Phase 3 443-48-1 4173
36
chenodeoxycholic acid Approved Phase 3 474-25-9 10133
37
Bezafibrate Approved, Investigational Phase 3 41859-67-0 39042
38
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
39
leucovorin Approved Phase 3 58-05-9 6006 143
40
Colchicine Approved Phase 3 64-86-8 2833 6167
41
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
42
Zidovudine Approved Phase 2, Phase 3 30516-87-1 35370
43
Copper Approved, Investigational Phase 3 7440-50-8 27099
44
Atorvastatin Approved Phase 3 134523-00-5 60823
45
Ursodeoxycholic acid Approved, Investigational Phase 3 128-13-2 31401
46
Budesonide Approved Phase 3 51333-22-3 63006 5281004
47
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
48
Tauroursodeoxycholic acid Experimental, Investigational Phase 3 14605-22-2 12443252
49
Tetrathiomolybdate Investigational Phase 3 16330-92-0
50 Hypoglycemic Agents Phase 2, Phase 3
51 Laxatives Phase 3
52 Cathartics Phase 3
53 Vitamin B Complex Phase 3
54 Folic Acid Antagonists Phase 3
55 Folate Phase 3
56 Vitamin B9 Phase 3
57 Tubulin Modulators Phase 3
58 Antimitotic Agents Phase 3
59 Lamivudine, zidovudine drug combination Phase 2, Phase 3
60 Angiogenesis Inhibitors Phase 3
61 Chelating Agents Phase 3
62 Copper Supplement Phase 3
63 Hypolipidemic Agents Phase 3
64 Lipid Regulating Agents Phase 3
65 Antimetabolites Phase 3
66 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
67 Anticholesteremic Agents Phase 3
68 carnitine Phase 3
69 Respiratory System Agents Phase 3
70 Hormones Phase 3
71 Anti-Asthmatic Agents Phase 3
72 Hormone Antagonists Phase 3
73 glucocorticoids Phase 3
74 Bronchodilator Agents Phase 3
75 Anti-Inflammatory Agents Phase 3
76
Sertraline Approved Phase 2 79617-96-2 68617
77
Pentoxifylline Approved, Investigational Phase 2 6493-05-6 4740
78
Moexipril Approved Phase 2 103775-10-6 91270
79
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
80
Ustekinumab Approved, Investigational Phase 2 815610-63-0
81
tannic acid Approved Phase 2 1401-55-4
82
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
83
Entecavir Approved, Investigational Phase 2 142217-69-4 153941
84
Rifaximin Approved, Investigational Phase 2 80621-81-4 6436173 46783403
85
Emtricitabine Approved, Investigational Phase 2 143491-57-0 60877
86
Methionine Approved, Nutraceutical Phase 2 63-68-3 6137
87
Tenofovir Experimental, Investigational Phase 2 147127-20-6 464205
88 Clofibric Acid Phase 1, Phase 2 882-09-7
89 Serotonin Uptake Inhibitors Phase 2
90 Psychotropic Drugs Phase 2
91 Neurotransmitter Agents Phase 2
92 Antidepressive Agents Phase 2
93 Phosphodiesterase Inhibitors Phase 2
94 Antioxidants Phase 2
95 Vasodilator Agents Phase 2
96 Platelet Aggregation Inhibitors Phase 2
97 Protective Agents Phase 2
98 Radiation-Protective Agents Phase 2
99
protease inhibitors Phase 2
100 HIV Protease Inhibitors Phase 2
101 Antihypertensive Agents Phase 2
102 Angiotensin-Converting Enzyme Inhibitors Phase 2
103 Janus Kinase Inhibitors Phase 2
104 Antineoplastic Agents, Immunological Phase 1, Phase 2
105 Adrenergic beta-Antagonists Phase 2
106 Gastrointestinal Agents Phase 2
107 Antiviral Agents Phase 2
108 Anti-Retroviral Agents Phase 2
109 Anti-HIV Agents Phase 2
110 Reverse Transcriptase Inhibitors Phase 2
111 Integrase Inhibitors Phase 2
112 HIV Integrase Inhibitors Phase 2
113 Raltegravir Potassium Phase 2
114 Immunoglobulins Phase 2
115 Antibodies Phase 2
116 Antibodies, Monoclonal Phase 2
117 E6011 Phase 2
118
Serotonin Investigational, Nutraceutical Phase 2 50-67-9 5202
119
Tigecycline Approved Phase 1 220620-09-7 5282044
120
Modafinil Approved, Investigational Phase 1 68693-11-8 4236
121
Adenosine Approved, Investigational Phase 1 58-61-7 60961
122
Trichostatin A Experimental Phase 1 58880-19-6
123 Immunoglobulins, Intravenous Phase 1
124 Immunoglobulin G Phase 1
125 Immunoglobulin M Phase 1
126 Central Nervous System Stimulants Phase 1
127 Cholestyramine Resin Phase 1
128 Cola Phase 1
129 Cholylsarcosine Phase 1
130 Pharmaceutical Solutions Phase 1
131
Pioglitazone Approved, Investigational 111025-46-8 4829
132
Lopinavir Approved 192725-17-0 92727
133
Ritonavir Approved, Investigational 155213-67-5 392622
134
Azathioprine Approved 446-86-6 2265
135
Pancrelipase Approved, Investigational 53608-75-6
136
Thrombin Approved, Investigational
137
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
138 Anesthetics
139 Rho(D) Immune Globulin
140 gamma-Globulins
141 Cytochrome P-450 Enzyme Inhibitors
142 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
143 Cytochrome P-450 CYP3A Inhibitors
144 Liver Extracts
145 Vitamins
146 Calciferol
147 Hepatitis C Antibodies
148 HIV Antibodies
149 pancreatin
150 Tissue Plasminogen Activator
151 Thromboplastin
152 Lipoprotein-associated coagulation inhibitor
153 Plasminogen
154 Chorionic Gonadotropin
155
Bilirubin 69853-43-6, 635-65-4 21252250 5280352

Interventional clinical trials:

(showing 154, show less)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis Unknown status NCT03345589 Phase 4 18-22mg/kg/d Ursodeoxycholic;13-15mg/kg/d Ursodeoxycholic
2 Double-blind, Double-dummy, Randomised, Crossover, Multicentre Phase IV Clinical Study Comparing the Effect of Ursofalk 500 mg Tablets od Versus Ursofalk 250 mg Capsules od on Liver Enzymes in the Treatment of Primary Biliary Cirrhosis Completed NCT01510860 Phase 4 UDCA (Ursodeoxycholic acid);UDCA (Ursodeoxycholic acid)
3 Abatacept For The Treatment Of Primary Biliary Cirrhosis With An Incomplete Biochemical Response To Ursodeoxycholic Acid Completed NCT02078882 Phase 4
4 Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis Completed NCT02557360 Phase 4
5 A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment Recruiting NCT03633227 Phase 4 Obeticholic Acid (OCA);Placebo
6 A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis Recruiting NCT02308111 Phase 4 Obeticholic Acid (OCA);Placebo
7 Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma Recruiting NCT02733809 Phase 4 Sorafenib
8 Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Duo to Nonresponse to Standard Therapy Not yet recruiting NCT04376528 Phase 4 Cyclosporin A;Mycophenolate Mofetil
9 Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy Not yet recruiting NCT04370145 Phase 4 Sulperazon;Teicoplanin;Meropenem Injection
10 Efficacy and Security of Bezafibrate in Patients With Primary Biliary Cirrhosis Without Biochemical Response to Ursodeoxycholic Acid: A Randomized, Double-blind, Placebo-controlled Trial Unknown status NCT02937012 Phase 3 Bezafibrate;Ursodeoxycholic Acid;Placebo (for Bezafibrate)
11 Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis: a Randomized Control Study Unknown status NCT02823353 Phase 3 Fenofibrate;UDCA
12 Fuzhenghuayu in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis Unknown status NCT02916290 Phase 3 Fuzhenghuayu;UDCA
13 Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid Unknown status NCT02823366 Phase 3 Fenofibrate;UDCA
14 Fuzhenghuayu for Patients With PBC Who Had An Inadequate Response to Ursodeoxycholic Acid Unknown status NCT02916641 Phase 3 Fuzhenghuayu;UDCA
15 METformin in Intrahepatic Cholestasis of Pregnancy (METRIC) Study Unknown status NCT03056274 Phase 2, Phase 3 Metformin;Ursodeoxycholic Acid
16 The Effect of Bezafibrate on Cholestatic Itch Unknown status NCT02701166 Phase 3 Bezafibrate;Placebo
17 Effectiveness of Ursodeoxycholic Acid Use in the Prevention of Gallstone Formation After Sleeve Gastrectomy: A Prospective Randomized Multicenter Placebo-Controlled Trial Unknown status NCT02721862 Phase 3 Ursodeoxycholic Acid;Placebo
18 Probiotics in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease- a Randomized Placebo-Controlled Cross-Over Trial Unknown status NCT00161148 Phase 3 Probiotics
19 Multicenter Randomized Trial Comparing Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis Unknown status NCT01398917 Phase 3
20 A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis Completed NCT01473524 Phase 3 Obeticholic Acid (OCA);Placebo
21 Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis Completed NCT00004784 Phase 3 methotrexate;ursodiol
22 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis Completed NCT00004748 Phase 3 colchicine;methotrexate;ursodiol
23 A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Clinical Trial to Investigate Safety and Efficacy of Tauroursodeoxycholic Acid Capsules in Treatment of Adult Primary Biliary Cirrhosis Completed NCT01857284 Phase 3 Tauroursodeoxycholic Acid Capsules;Ursodeoxycholic Acid Capsules
24 Randomized Controlled Pilot Study of Combivir for Patients With Primary Biliary Cirrhosis Completed NCT00490620 Phase 2, Phase 3 Combination antiviral therapy;Placebo
25 Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis Completed NCT00844402 Phase 3 Atorvastatin
26 Ursodiol-Methotrexate for Primary Biliary Cirrhosis Completed NCT00006168 Phase 3 Methotrexate
27 Phase III Trial of Tetrathiomolybdate (TM) in Primary Biliary Cirrhosis Completed NCT00805805 Phase 3 Tetrathiomolybdate
28 Multicenter, Randomized, Double-blind Placebo Controlled Trial of Bezafibrate for the Treatment of Primary Biliary Cirrhosis in Patients With Incomplete Response to Ursodesoxycholic Acid Therapy. Completed NCT01654731 Phase 3 Bezafibrate;placebo
29 Evaluate the Efficacy And Safety Of TUDCA Compare UDCA In The Treatment Of Cholestatic Liver Disease-PBC by A Randomized,Double-Blind,Double Dummy,Parallel-Controlled,Multicenter Trial and The Consecutive Treatment By TUDCA Completed NCT01829698 Phase 3 tauroursodeoxycholic;ursodeoxycholic acid
30 A Phase 3 Study to Evaluate the Place of Budesonide in the Treatment of GVHD Completed NCT00128739 Phase 3 Budesonide
31 Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina Active, not recruiting NCT03696940 Phase 3 L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg;Atorvastatin 10mg
32 Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis Not yet recruiting NCT04167358 Phase 3 Linerixibat
33 An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) Suspende